Tracy Newbold
Chief Tech/Sci/R&D Officer bei LEXICON PHARMACEUTICALS, INC.
Profil
Tracy Newbold is currently the Vice President-Clinical Operations at Lexicon Pharmaceuticals, Inc. Prior to this role, Tracy held positions as Senior Director-Operations at United Therapeutics Corp.
from 2011 to 2017, and as Senior Director-Clinical Operations at Atox Bio Ltd.
from 2017 to 2020.
Tracy also briefly worked as Senior Director-Clinical Operations at Immunovant, Inc. in 2020.
Tracy obtained an undergraduate degree from The University of North Carolina at Chapel Hill.
Aktive Positionen von Tracy Newbold
| Unternehmen | Position | Beginn |
|---|---|---|
| LEXICON PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01.07.2021 |
Ehemalige bekannte Positionen von Tracy Newbold
| Unternehmen | Position | Ende |
|---|---|---|
Atox Bio Ltd.
 Atox Bio Ltd. BiotechnologyHealth Technology Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel. | Corporate Officer/Principal | 01.01.2020 |
| UNITED THERAPEUTICS CORPORATION | Chief Operating Officer | 01.01.2017 |
| IMMUNOVANT, INC. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Tracy Newbold
| The University of North Carolina at Chapel Hill | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| UNITED THERAPEUTICS CORPORATION | Health Technology |
| LEXICON PHARMACEUTICALS, INC. | Health Technology |
| IMMUNOVANT, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel. | Health Technology |
